Cellectar Biosciences (CLRB) vs Pasithea Therapeutics (KTTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed Cellectar Biosciences (CLRB) over the past year, losing 46.2% versus a loss of 70.7%. Over five years, KTTA leads with a -99.3% price change compared with -99.5% for CLRB. Pasithea Therapeutics is the larger company by market cap ($15.0 million vs $13.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLRB | KTTA |
|---|---|---|
| Share price | $1.42 | $0.4501 |
| Market cap | $13.37M | $15.04M |
| 1-day change | +1.08% | +2.09% |
| YTD return | -52.54% | -65.82% |
| 1-year return | -70.71% | -46.23% |
| 5-year return | -99.49% | -99.26% |
| EPS (TTM) | $-3.46 | $-1.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.07 | $2.06 |
| 52-week low | $1.34 | $0.281 |
| Distance from 52-week high | -72.09% | -78.15% |
| Analyst consensus | none | none |
| Avg. price target upside | +712.72% | +566.52% |
| Average volume | 63.86K | 225.69K |
| Shares outstanding | 9.45M | 33.41M |
| Employees | 11 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KTTA has outperformed CLRB by 24.5 percentage points over the past year.
About Cellectar Biosciences
CLRB stock →Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CLRB vs KTTA FAQ
Which is bigger, Cellectar Biosciences or Pasithea Therapeutics?
Pasithea Therapeutics (KTTA) is larger, with a market capitalization of $15.04M compared with $13.37M for Cellectar Biosciences (CLRB).
Which stock has performed better over the past year, CLRB or KTTA?
KTTA returned -46.23% over the past 12 months, compared with -70.71% for CLRB (price return, excluding dividends). Past performance does not predict future results.
Are Cellectar Biosciences and Pasithea Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.